JPMorgan Chase & Co. Sells 176,780 Shares of Certara, Inc. (NASDAQ:CERT)

JPMorgan Chase & Co. cut its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 4.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,872,515 shares of the company's stock after selling 176,780 shares during the period. JPMorgan Chase & Co. owned 2.41% of Certara worth $45,347,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Certara by 36.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,012 shares of the company's stock valued at $374,000 after acquiring an additional 7,158 shares in the last quarter. TD Asset Management Inc boosted its stake in shares of Certara by 10.9% during the 2nd quarter. TD Asset Management Inc now owns 101,728 shares of the company's stock worth $1,409,000 after acquiring an additional 10,036 shares in the last quarter. Choreo LLC acquired a new position in shares of Certara in the 2nd quarter worth $348,000. Oppenheimer Asset Management Inc. raised its position in shares of Certara by 45.7% during the second quarter. Oppenheimer Asset Management Inc. now owns 197,724 shares of the company's stock worth $2,738,000 after purchasing an additional 61,980 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Certara by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 573,660 shares of the company's stock valued at $7,945,000 after purchasing an additional 43,403 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Performance

CERT stock traded up $0.12 during midday trading on Monday, hitting $11.33. 1,048,298 shares of the company traded hands, compared to its average volume of 1,000,766. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -56.65, a price-to-earnings-growth ratio of 5.86 and a beta of 1.52. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business has a 50 day simple moving average of $10.76 and a 200-day simple moving average of $12.08.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.06 EPS. As a group, equities research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CERT shares. Robert W. Baird decreased their target price on shares of Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. Finally, UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Certara has a consensus rating of "Hold" and a consensus target price of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.